3、适应症：膝骨关节炎 4、注册分类：中药 1.1 类 关于子公司获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，博济医药科技股份有限公司（以下简称"公司"）全资子公司广州博 济新药临床研究中心有限公司申报的"卿芷软膏"获得国家药品监督管理局核准 签发的《药物临床试验批准通知书》。现将相关情况公告如下： 一、 药物基本情况 1、通知书编号：2025LP02962 2、药品名称：卿芷软膏 证券代码：300404 证券简称：博济医药 公告编号：2025-082 博济医药科技股份有限公司 5、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 2025 年 8 月 22 日受理的卿芷软膏符合药品注册的有关要求，在进一步完善临床 试验方案的基础上，同意本品开展用于膝骨关节炎的临床试验。 二、 药物其他情况 露义务。由于药品研发的特殊性，药品从临床试验到获准上市的周期长、环节多， 易受到诸多不可预测的因素影响，临床试验进度及结果、未来产品市场竞争形势 等均存在不确定性。 "卿芷软膏"为多味饮片在中医药理论指导下组方而成 ...

Core Insights - Boji Pharmaceutical is a leading provider of new drug research and development outsourcing services in China, established in 2002 and listed on the Shenzhen Stock Exchange in 2015 [1] Group 1: Business Overview - Boji Pharmaceutical offers comprehensive new drug R&D services, including preclinical research, clinical research, technology transfer, and consulting services [1] - The company operates in the pharmaceutical and biotechnology sector, specifically in medical services and R&D outsourcing, with relevant concepts including Helicobacter pylori and hepatitis treatment [1] Group 2: Financial Performance - For Q3 2025, Boji Pharmaceutical reported revenue of 584 million yuan, ranking 16th out of 29 in the industry, significantly lower than the top competitor WuXi AppTec at 32.857 billion yuan [2] - The net profit for the same period was 23.8675 million yuan, placing the company 21st in the industry, again far behind WuXi AppTec's 12.206 billion yuan [2] Group 3: Financial Ratios - As of Q3 2025, Boji Pharmaceutical's debt-to-asset ratio was 33.62%, higher than the previous year's 31.81% and above the industry average of 22.79% [3] - The gross profit margin was 28.83%, down from 32.19% year-on-year and below the industry average of 37.70% [3] Group 4: Leadership and Shareholder Information - The chairman and controlling shareholder, Wang Tingchun, saw his salary decrease from 414,000 yuan in 2023 to 391,000 yuan in 2024 [4] - As of September 30, 2025, the number of A-share shareholders increased by 18.91% to 29,600, while the average number of circulating A-shares held per shareholder decreased by 15.21% [5] Group 5: Business Developments - Clinical business showed stable growth with clinical research service revenue of 290 million yuan and new contract value of 752 million yuan, achieving a business gross margin of 30.6% [5] - Non-clinical business performance varied, with preclinical research service revenue at 40.87 million yuan and other consulting services at 23.49 million yuan [5] - The company has made progress in self-developed projects, including innovative traditional Chinese medicine [5]

Core Viewpoint - Boji Pharmaceutical (300404.SZ) reported its Q3 2025 results, highlighting a decrease in institutional ownership and changes in public fund holdings [1] Institutional Investors - As of October 28, 2025, four institutional investors disclosed holdings in Boji Pharmaceutical, totaling 10.34 million shares, which represents 2.68% of the company's total equity [1] - The institutional ownership decreased by 1.39 percentage points compared to the previous quarter [1] Public Funds - One public fund, Dongcai Yuanjian Growth Mixed Initiation A, increased its holdings slightly in the current period [1] - A total of 28 public funds that were previously disclosed did not report their holdings this quarter, including notable funds such as Nuoan Pioneer Mixed A and Nuoan Preferred Return Mixed A [1] Foreign Investment - The foreign investment landscape saw the non-disclosure of BARCLAYS BANK PLC in the current period compared to the previous quarter [1]

Core Viewpoint - The company, Boji Pharmaceutical, announced a comprehensive review of its assets, indicating potential impairment losses for certain assets as a precautionary measure [2] Asset Review Summary - The company and its subsidiaries conducted a thorough examination of various assets, including inventories, receivables, contract assets, fixed assets, construction in progress, intangible assets, goodwill, and assets held for sale [2] - The assessment revealed signs of impairment in some assets, leading the company to prepare for potential asset impairment losses [2] Impairment Losses - For the third quarter of 2025, the company recognized an asset impairment loss of 1,916,089.27 yuan and a credit impairment loss of 4,998,909.35 yuan [2] - The company also reversed impairment provisions amounting to 210,397.52 yuan and wrote off impairment provisions of 97,193.47 yuan [2]

Core Viewpoint - Boji Pharmaceutical (300404.SZ) reported a revenue of 584 million yuan for the first three quarters of 2025, reflecting a year-on-year growth of 5.06% [1] Financial Performance - The net profit attributable to shareholders of the listed company was 21.91 million yuan, representing a year-on-year decrease of 49.36% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 14.98 million yuan, down 57.06% year-on-year [1] - Basic earnings per share stood at 0.0571 yuan [1]

证券代码：300404 证券简称：博济医药 公告编号：2025-081 博济医药科技股份有限公司 关于计提资产减值损失、信用减值损失及核销资产的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次计提资产减值损失、信用减值损失情况概述 （一）本次计提资产减值损失、信用减值损失的原因 博济医药科技股份有限公司（以下简称"公司"）本次计提资产减值准备， 是依照《企业会计准则》及公司会计政策的相关规定进行的。公司及下属子公司 对 2025 年第三季度末各类存货、应收款项、合同资产、固定资产、在建工程、 无形资产、商誉、持有待售资产等资产进行了全面清查，对各类存货的可变现净 值、应收款项及合同资产回收的可能性、固定资产、在建工程、无形资产及持有 待售资产的可变现性进行了充分的评估和分析，认为上述资产中部分资产存在一 定的减值迹象，本着谨慎性原则，公司需对可能发生资产减值损失的相关资产进 行计提减值准备。 （二）本次计提资产减值损失的资产范围和总金额 公司及下属子公司对 2025 年第三季度末存在可能发生减值迹象的资产（范 围包括合同资产、存货）进行全面清查和 ...

Financial Performance - Q3 2025 revenue reached ¥222,869,199.85, an increase of 3.78% year-over-year, while year-to-date revenue was ¥584,317,656.85, up 5.06% compared to the previous year[5] - Net profit attributable to shareholders was ¥6,344,040.03, down 51.73% year-over-year, and year-to-date net profit was ¥21,913,904.30, a decrease of 49.36%[5] - Basic earnings per share for the quarter was ¥0.0165, a decline of 52.03%, while year-to-date basic earnings per share was ¥0.0571, down 49.60%[5] - Total comprehensive income for the year-to-date was ¥23,471,634.26, down 47.83% from the previous year[11] - The net profit for the current period is CNY 23,867,516.19, a decrease of 47.4% compared to CNY 45,361,752.11 in the previous period[26] - The total profit for the current period is CNY 18,330,632.81, down from CNY 31,163,247.92, reflecting a decline of 41.3%[26] - Operating profit for the current period is CNY 18,609,104.55, compared to CNY 31,224,117.99 in the previous period, indicating a decrease of 40.8%[26] - The total comprehensive income for the current period is CNY 23,471,634.26, a decrease of 47.8% from CNY 44,992,255.06 in the previous period[26] Assets and Liabilities - Total assets increased to ¥1,587,919,783.62, reflecting a growth of 9.47% from the end of the previous year[5] - Total liabilities increased to ¥533,808,008.31 from ¥448,838,881.46, reflecting a growth of 19.0%[24] - The company's equity attributable to shareholders rose to ¥1,020,241,096.25 from ¥973,381,474.22, an increase of 4.8%[24] - Non-current assets totaled ¥663,301,584.37, slightly down from ¥670,313,529.45, a decrease of 1.5%[23] Cash Flow - Cash flow from operating activities for the year-to-date was ¥7,794,974.90, a significant increase of 148.60% compared to the same period last year[13] - Cash flow from operating activities shows a net inflow of CNY 7,794,974.90, a significant improvement from a net outflow of CNY 16,040,097.77 in the previous period[27] - Cash flow from investing activities resulted in a net outflow of CNY 151,446,023.16, slightly improved from CNY 186,702,227.12 in the previous period[28] - Cash flow from financing activities generated a net inflow of CNY 18,593,184.08, compared to a net outflow of CNY 62,737,410.37 in the previous period[28] Shareholder Information - The total number of common shareholders at the end of the reporting period is 29,555[14] - The largest shareholder, Wang Tingchun, holds 30.77% of the shares, amounting to 118,674,370 shares, with 26,603,600 shares pledged[14] - The number of shares with limited sales conditions held by Wang Tingchun is 89,005,777, which are locked for 36 months[16] - As of September 30, 2025, the company's total share capital has increased from 381,989,708 shares to 385,556,078 shares[18] Operational Highlights - The company has signed new business contracts worth approximately 1.248 billion RMB, representing a year-on-year growth of about 9.85%[17] - The company received three invention patents during the reporting period, including methods for the preparation of specific drugs[19] - The company obtained clinical trial approval for its drug "FCZR" from the National Medical Products Administration[18] - The company's governance structure has been optimized following the completion of the capital change registration[18] Costs and Expenses - Total operating costs amounted to ¥554,800,483.18, up from ¥519,937,507.73, reflecting a rise of 6.7%[25] - Research and development expenses decreased to ¥38,925,834.02 from ¥44,450,607.56, a decline of 12.4%[25] - The company's cash and cash equivalents decreased to ¥143,763,081.57 from ¥270,133,867.18, a decline of 46.8%[21] - Accounts receivable increased to ¥195,581,145.66 from ¥169,703,594.65, representing a growth of 15.2%[21] - Inventory rose to ¥242,017,600.69 from ¥189,485,440.64, marking an increase of 27.7%[21] Investment Income - The company experienced a 71.48% decrease in investment income, amounting to ¥422,611.89, mainly due to reduced financial product returns[11] - The company reported a 602.31% increase in trading financial assets, totaling ¥166,292,060.25, primarily due to the purchase of financial products[9] - Contract assets rose by 58.46% to ¥126,170,228.44, attributed to increased revenue during the period[9]

Core Points - The company Boji Pharmaceutical announced that its wholly-owned subsidiary, Guangzhou Huasheng Pharmaceutical Co., Ltd., has received the drug registration certificate from the National Medical Products Administration for "Compound Polyethylene Glycol Electrolyte Powder (III)" [2] Group 1 - The approval of the drug registration certificate marks a significant milestone for the company in expanding its product portfolio [2] - This development may enhance the company's market position in the pharmaceutical industry [2]

Core Viewpoint - The company Boji Pharmaceutical has received a drug registration certificate for its product, Compound Polyethylene Glycol Electrolyte Powder, from the National Medical Products Administration, indicating a significant regulatory milestone for the company [1] Group 1 - The product is intended for bowel cleansing preparation prior to endoscopic or radiological examinations and colon surgeries, highlighting its clinical application [1] - The registration certificate was issued to the company's wholly-owned subsidiary, Guangzhou Huasheng Pharmaceutical Co., Ltd., indicating the company's operational structure and focus on specialized subsidiaries [1]

Core Viewpoint - The approval of "Compound Polyethylene Glycol Electrolyte Powder (III)" by the National Medical Products Administration indicates a significant advancement for the company in the pharmaceutical market, particularly for bowel preparation in adults undergoing endoscopic or radiological examinations and colon surgeries [1] Company Summary - The subsidiary Guangzhou Huasheng Pharmaceutical Co., Ltd. has received the drug registration certificate for "Compound Polyethylene Glycol Electrolyte Powder (III)" [1] - This drug is specifically designed for bowel cleansing preparation in adult patients prior to endoscopic or radiological examinations and colon surgeries [1] Market Potential - According to data from Minet, the sales scale of "Compound Polyethylene Glycol Electrolyte Powder (III)" in urban and county-level public hospitals in China is approximately 220 million RMB in 2024 [1] - The approval signifies that the drug meets the national pharmaceutical review technical standards and can be produced and sold in the domestic market upon compliance with production quality management regulations [1]